Breaking Finance News

A report released today by Citigroup about Alkermes (NASDAQ:ALKS) ups the target price to $53.00

Alkermes (NASDAQ:ALKS) had its price target upped to $53.00 by Citigroup in an issued report announced Tuesday September 27, 2016. The latest stock price target implies a possible upside of 0.08% based on the company's most recent stock price close.

On 7/29/2016, Barclays Capital released a statement for Alkermes (NASDAQ:ALKS) bumped up the target price from $65.00 to $66.00 that suggested an upside of 0.32%.

Boasting a price of $49.23, Alkermes (NASDAQ:ALKS) traded 1.40% higher on the day. With the last stock price close up 14.62% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Alkermes has recorded a 50-day average of $46.78 and a two hundred day average of $42.98. Trading volume was down over the average, with 611,080 shares of ALKS changing hands under the typical 830,123

Recent Performance Chart

Alkermes (NASDAQ:ALKS)

Alkermes has with a one year low of $27.14 and a one year high of $80.71 and has a market capitalization of $0.

A total of 10 analysts have released a report on Alkermes. Two brokerages rating the stock a strong buy, 2 firms rating the stock a buy, 6 brokers rating the stock a hold, one equity analyst rating the company a underperform, and finally 0 brokerages rating the stock a sell with a 12-month price target of $44.40.

General Company Details For Alkermes (NASDAQ:ALKS)

Alkermes Public Limited Company is a biopharmaceutical company. The Company is engaged in researching, developing and commercializing, both with partners and on its own, pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of approximately 20 products and a clinical pipeline of product candidates that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis. Its products include ARISTADA, VIVITROL, RISPERDAL CONSTA, INVEGA SUSTENNA/XEPLION & INVEGA TRINZA, AMPYRA/FAMPYRA, BYDUREON, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, Aripiprazole Lauroxil Two-Month Dose, ALKS 7119 and RDB 1450. Its product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release technology.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *